MIDAS-2:一个增强的贝叶斯平台设计,用于免疫疗法组合与子组疗效探索
Liwen Su1, Xin Chen1, Jingyi Zhang1
1Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
Journal of biopharmaceutical statistics
|December 22, 2023
概括
新的MIDAS-2试验设计有效地选免疫疗法组合并确定有效的子组. 这种适应性框架通过改善不同患者群体的治疗选择来加速癌症药物开发.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 免疫疗法组合已经改变了癌症治疗,但快速选最佳疗法和子组疗效是具有挑战性的.
- 创新和高效的临床试验设计对于推动癌症治疗开发至关重要.
- 现有的平台设计往往缺乏集成的子组分析能力.
研究的目的:
- 扩大MIDAS设计,以纳入免疫疗法组合的子组探索.
- 提出一个增强的贝叶斯信息借用平台设计,MIDAS-2.
- 在统一的框架内,能够有效选有前途的组合策略及其子组效应.
主要方法:
- 利用回归模型来描述患者子组内的疗效模式.
- 实施贝叶斯层次模型用于信息借用,以提高小组中的试验效率.
- 使用时间趋势校准来缓解试验期间潜在的基线偏移.
主要成果:
- MIDAS-2显示了识别有效药物组合和有前途的子组的高概率.
- 设计方便选择针对特定患者子组量身定制的最佳治疗方法.
- 拟议的设计显示了对小时间趋势偏移的稳定性,并且在对显著偏移进行校准后控制了I型错误.
结论:
- 在免疫治疗中,MIDAS-2为药物查和子组探索提供了适应性框架.
- 这种设计通过高效,准确和综合的方法加速免疫治疗的发展.
- MIDAS-2通过优化基于子组疗效的治疗选择来支持个性化医疗.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
00:07Quantification of Protein Interaction Network Dynamics using Multiplexed Co-Immunoprecipitation
Published on: August 21, 2019
8.4K
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...